GlassScriptPhysician profile
Larry W Linnell
NPI 1346242179
$185.79
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.57 · 2020: $50.10 · 2021: $11.40 · 2022: $40.72.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $45.94 | 2019-2022 | |
| Endogastric Solutions, INC | $40.26 | 2019 | |
| Abbvie INC. | $24.73 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.49 | 2020 | |
| Novo Nordisk INC | $15.61 | 2019 | |
| Genentech USA, INC. | $15.41 | 2020 | |
| Merck Sharp & Dohme LLC | $15.21 | 2022 | |
| Glaxosmithkline, LLC. | $11.14 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Linnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.